Clinical Study (internal clinical assessment) Report

COVID-19 Antigen Rapid Test (Latex)

Prepared By: **Yanhua ZHANG Date:**   **02/09/2020**

Reviewed By: **Qian XU**   **Date:**   **02/09/2020**

Approval By: **Zhong WANG**   **Date:**   **03/09/2020**

1   Purpose:

To determine the performance of COVID-19 Antigen Rapid Test compared to a commercially available competitor assay.

2   Operation Information

2.3 Materials:

COVID-19 Antigen Rapid Lot：COV2008003L-T

Competitor assay: Novel Coronavirus (SARS-COV-2) Real Time Multiplex RT-PCR Kit produced by Shanghai ZJ Bio-Tech Co., Ltd., a commercial SARS-COV-2 kit approved by CFDA, is referred herein as the "gold standard" reagent.

3   Method:

180 samples of the novel coronavirus SARS-CoV-2 and 90 samples of healthy people were included in the testing plan. A total of 90 saliva samples, 90 sputum samples and 90 stool samples were tested in the COVID-19 Antigen Rapid assay and the Novel Coronavirus (SARS-COV-2) real-time multiplex RT-PCR kit, and the clinical sensitivity, specificity and overall agreement between the 2 assays calculated.

4.   Clinical research results and analysis

4.1 Clinical research results

4.1.1 The Test results were as follows:

Novel Coronavirus	Covid 19 antigen Rapid Test			RT-PCR
	Saliva	Stool	Sputum	throat swab
Healthy 1	-	-	-	-
Healthy 2	-	-	-	-
Healthy 3	-	-	-	-
Healthy 4	-	-	-	-
Healthy 5	-	-	-	-
Healthy 6	-	-	-	-
Healthy 7	-	-	-	-
Healthy 8	-	-	-	-
Healthy 9	-	-	-	-
Healthy 10	-	-	-	-
Healthy 11	-	-	-	-
Healthy 12	-	-	-	-
Healthy 13	-	-	-	-
Healthy 14	-	-	-	-

Healthy 15	-	-	-	-
Healthy 16	-	-	-	-
Healthy 17	-	-	-	-
Healthy 18	-	-	-	-
Healthy 19	-	-	-	-
Healthy 20	-	-	-	-
Healthy 21	-	-	-	-
Healthy 22	-	-	-	-
Healthy 23	-	-	-	-
Healthy 24	-	-	-	-
Healthy 25	-	-	-	-
Healthy 26	-	-	-	-
Healthy 27	-	-	-	-
Healthy 28	-	-	-	-
Healthy 29	-	-	-	-
Healthy 30	-	-	-	-

	Covid 19 antigen Rapid Test			RT-PCR	
DAY	Saliva	Stool	Sputum	throat swab	throat swab（notes）
Day 1 of disease onset	+	+	+	+	
Day 9 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 6 of disease onset	+	+	+	+	
Day 2 of disease onset	+	+	-	+	
Day 5 of disease onset	+	+	+	+	
Day 8 of disease onset	+	+	+	+	
Day 4 of disease onset	+	+	+	+	
Day 7 of disease onset	+	+	+	+	
Day 7 of disease onset	+	+	+	+	
Day 2 of disease onset	+	+	+	+	
Day 2 of disease onset	-	-	+	+	confirm by retest
Day 2 of disease onset	+	+	+	+	
Day 1 of disease onset	+	+	+	+	
Day 1 of disease onset	+	+	+	+	
Day 6 of disease onset	+	+	+	+	

Day 4 of disease onset	+	+	+	+	
Day 4 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 1 of disease onset	+	+	+	+	
Day 2 of disease onset	+	+	+	+	
Day 3 of disease onset	-	+	+	+	
Day 2 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 6 of disease onset	+	+	+	+	
Day 1 of disease onset	-	-	+	+	confirm by retest
Day 6 of disease onset	+	+	+	+	
Day 8 of disease onset	+	+	+	+	
Day 4 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 2 of disease onset	+	+	+	+	
Day 5 of disease onset	+	+	+	+	
Day 7 of disease onset	+	+	+	+	
Day 9 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 1 of disease onset	-	-	+	+	confirm by retest
Day 2 of disease onset	+	+	+	+	
Day 5 of disease onset	+	+	+	+	
Day 4 of disease onset	+	+	-	+	
Day 3 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 5 of disease onset	+	+	+	+	
Day 5 of disease onset	+	+	+	+	
Day 9 of disease onset	+	+	+	+	
Day 7 of disease onset	+	+	+	+	
Day 2 of disease onset	-	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 1 of disease onset	-	+	-	+	
Day 1 of disease onset	+	+	+	+	
Day 2 of disease onset	+	+	+	+	
Day 4 of disease onset	+	+	+	+	
Day 3 of disease onset	+	+	+	+	
Day 7 of disease onset	+	+	+	+	

Day 5 of disease onset	+	+	+	+	
Day 6 of disease onset	+	+	+	+	
Day 4 of disease onset	+	+	+	+	
Day 6 of disease onset	+	+	+	+	
Day 1 of disease onset	+	+	+	+	
Day 2 of disease onset	+	+	+	+	

4.2 The above results are summarized as follows：

Saliva Sample		Gold standard reagent		Total
		Positive	Negative	
Test reagent	Positive	54	0	54
	Negative	6	30	36
Total		60	30	90

Sputum Sample		Gold standard reagent		Total
		Positive	Negative	
Test reagent	Positive	57	0	57
	Negative	3	30	33
Total		60	30	90

Stool Sample		Gold standard reagent		Total
		Positive	Negative	
Test reagent	Positive	57	0	57
	Negative	3	30	33
Total		60	30	90

Result analysis

Saliva samples: The Novel Coronavirus Spike Glycoprotein Detection Kit showed 90% sensitivity and 100% specificity in saliva samples.

Clinical sensitivity (%) = [54 / (54 + 6)] ×100% = 90%

Clinical specificity (%) = [30/ (0+ 30)] ×100% = 100%

Total agreement rate (%) = [(54 +30) / (54 + 6+ 0+ 30)] ×100% = 93.3%

Sputum samples: The Novel Coronavirus Spike Glycoprotein Detection Kit showed 95%

sensitivity and 100% specificity in sputum samples.

Clinical sensitivity (%) = [57/ (57+ 3)] ×100% = 95%

Clinical specificity (%) = [30/ (0+ 30)] ×100% = 100%

Total agreement rate (%) = [(57 +30) / (57 +3+ 0+ 30)] ×100% = 96.7%

Stool samples: The Novel Coronavirus Spike Glycoprotein Detection Kit showed 95% sensitivity and 100% specificity in stool samples.

Clinical sensitivity (%) = [57/ (57+ 3)] ×100% = 95%

Clinical specificity (%) = [30/ (0+ 30)] ×100% = 100%

Total agreement rate (%) = [(57 +30) / (57 +3+ 0+ 30)] ×100% = 96.7%

5 Discussion and conclusion

The overall clinical performance of the Joinstar COVID-19 Antigen Rapid Test was comparable with the data obtained in the Novel Coronavirus (SARS-COV-2) Real Time Multiplex RT-PCR assay and supports the use of the Joinstar assay in the detection of SARS-CoV-2.